New lessons for an old problem: ASSET open-label extension

被引：0
|
作者：
Del Galdo, Francesco [1 ,2 ]
机构：
[1] Univ Leeds, Inst Rheumat & Musculoskeletal Med, Scleroderma Programme, Leeds LS7 4SA, W Yorkshire, England
[2] Natl Inst Hlth, Res Biomed Res Ctr, Leeds, W Yorkshire, England
来源：
LANCET RHEUMATOLOGY | 2020年 / 2卷 / 12期
关键词：
ABATACEPT; EFFICACY; SAFETY; CTLA4;
D O I：
10.1016/S2665-9913(20)30379-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：E726 / E727
页数：2
相关论文
共 50 条
  • [21] Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
    Humbert, Marc
    McLaughlin, Vallerie
    Gibbs, J. Simon R.
    Gomberg-Maitland, Mardi
    Hoeper, Marius M.
    Preston, Ioana R.
    Souza, Rogerio
    Waxman, Aaron B.
    Ghofrani, Hossein-Ardeschir
    Subias, Pilar Escribano
    Feldman, Jeremy
    Meyer, Gisela
    Montani, David
    Olsson, Karen M.
    Manimaran, Solaiappan
    Pena, Janethe de Oliveira
    Badesch, David B.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (01)
  • [22] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
    Genovese, M. C.
    Fay, J.
    Beyer, D.
    Iglesias-Rodriguez, M.
    Simon, A.
    Martincova, R.
    Burmester, G. R.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S69 - S70
  • [23] The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
    Frank, Samuel
    Testa, Claudia
    Edmondson, Mary C.
    Goldstein, Jody
    Kayson, Elise
    Leavitt, Blair R.
    Oakes, David
    O'Neill, Christine
    Vaughan, Christina
    Whaley, Jacquelyn
    Gross, Nicholas
    Gordon, Mark Forrest
    Savola, Juha-Matti
    CNS DRUGS, 2022, 36 (11) : 1207 - 1216
  • [24] LONG-TERM PERAMPANEL USE IN OPEN-LABEL EXTENSION STUDIES
    Rektor, Ivan
    Krauss, Gregory L.
    Inoue, Yushi
    Kaneko, Sunao
    Williams, Betsy
    Patten, Anna
    Bibbiani, Francesco
    Laurenza, Antonio
    Wechsler, Robert T.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A23 - A23
  • [25] INTERIM ANALYSIS OF NINTEDANIB IN AN OPEN-LABEL EXTENSION OF THE INPULSIS® TRIALS (INPULSIS®-ON)
    Corte, T.
    Crestani, B.
    Ogura, T.
    Pelling, K.
    Coeck, C.
    Quaresma, M.
    Kreuter, M.
    Kaye, M.
    RESPIROLOGY, 2016, 21 : 66 - 66
  • [26] Results of switching to laquinimod in the open-label extension phase of the BRAVO study
    Vollmer, T.
    Sorensen, P. S.
    Selmaj, K.
    Zipp, F.
    Havrdova, E.
    Cohen, J.
    Sidi, Y.
    Gorfine, T.
    Arnold, D.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 489 - 489
  • [27] Design, objectives, execution and reporting of published open-label extension studies
    Megan, Bowers
    Pickering, Ruth M.
    Weatherall, Mark
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2012, 18 (02) : 209 - 215
  • [28] Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients
    Genovese, Mark C.
    Fay, Jon
    Parrino, Janie
    Beyer, Doris
    Iglesias-Rodriguez, Melitza
    Graham, Neil
    Boddy, Alex
    Simon, J-Abraham
    Martincova, Renata
    Burmester, Gerd R.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [29] MAINTENANCE OF EFFICACY, SAFETY AND TOLERABILITY OF ARMODAFINIL: AN OPEN-LABEL EXTENSION STUDY
    Black, J.
    Hull, S. G.
    Tiller, J.
    Yang, R.
    Harsh, J. R.
    SLEEP, 2009, 32 : A139 - A139
  • [30] An open-label extension study of alendronate treatment in elderly women with osteoporosis
    Downs, RW
    Bone, HG
    McIlwain, H
    Baker, MZ
    Yates, AJ
    Lombardi, A
    Krupa, D
    Harning, R
    CALCIFIED TISSUE INTERNATIONAL, 1999, 64 (06) : 463 - 469
12345